MA41742A1 - Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers. - Google Patents
Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers.Info
- Publication number
- MA41742A1 MA41742A1 MA41742A MA41742A MA41742A1 MA 41742 A1 MA41742 A1 MA 41742A1 MA 41742 A MA41742 A MA 41742A MA 41742 A MA41742 A MA 41742A MA 41742 A1 MA41742 A1 MA 41742A1
- Authority
- MA
- Morocco
- Prior art keywords
- cancers
- determination
- threshold
- positivity
- overexpression
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 230000002018 overexpression Effects 0.000 title 1
- 238000011002 quantification Methods 0.000 abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011895 specific detection Methods 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une méthode facile et pratique pour la détermination du seuil de positivité (threshold) pour la quantification de l’expression du gène her2 surexprimé dans le cas du cancer du sein, de l’estomac ainsi que dans d’autres types de cancers. La détection spécifique et la quantification des transcrits du gène her2 et les gènes de référence se font par la méthode de transcription inverse-pcr en temps réel (rtqpcr) en format multiplexe ou simplexe. Un échantillon sera considéré comme positif si son taux d’expression du gène her2 est supérieur au seuil de positivité calculé par la présente méthode.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MA41742A MA41742B1 (fr) | 2017-12-29 | 2017-12-29 | Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers. |
| PCT/MA2018/050021 WO2019132640A1 (fr) | 2017-12-29 | 2018-12-28 | Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MA41742A MA41742B1 (fr) | 2017-12-29 | 2017-12-29 | Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41742A1 true MA41742A1 (fr) | 2019-08-30 |
| MA41742B1 MA41742B1 (fr) | 2020-02-28 |
Family
ID=65352067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41742A MA41742B1 (fr) | 2017-12-29 | 2017-12-29 | Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers. |
Country Status (2)
| Country | Link |
|---|---|
| MA (1) | MA41742B1 (fr) |
| WO (1) | WO2019132640A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA35294B1 (fr) * | 2012-12-27 | 2014-08-01 | Mascir Moroccan Foundation For Advanced Science Innovation & Res | Sondes et amorces pour detecter le gene her2 en format multiplexe et ses applications dans le choix du traitement du cancer de sein her2 |
| KR101586846B1 (ko) * | 2014-02-25 | 2016-01-19 | 주식회사 옵티팜 | 개선된 유방암에 대한 정보제공 방법 및 그 진단용 키트 |
| MA37437B1 (fr) * | 2014-10-17 | 2016-12-30 | Mascir (Morrocan Found For Advanced Science Innovation & Research) | Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement |
-
2017
- 2017-12-29 MA MA41742A patent/MA41742B1/fr unknown
-
2018
- 2018-12-28 WO PCT/MA2018/050021 patent/WO2019132640A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MA41742B1 (fr) | 2020-02-28 |
| WO2019132640A1 (fr) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Histone demethylase KDM5D upregulation drives sex differences in colon cancer | |
| Yu et al. | Long non‐coding RNA linc00261 suppresses gastric cancer progression via promoting Slug degradation | |
| Biddle et al. | CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition | |
| Pinho et al. | E-cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V | |
| Chen et al. | Upregulated expression of long noncoding RNA SNHG15 promotes cell proliferation and invasion through regulates MMP2/MMP9 in patients with GC | |
| Kutlu et al. | Metastatic lymph node ratio successfully predicts prognosis in western gastric cancer patients | |
| Ke et al. | ALG3 contributes to the malignancy of non-small cell lung cancer and is negatively regulated by MiR-98-5p | |
| Lokman et al. | Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome | |
| JP6810396B2 (ja) | Ｐｄ−ｌ１（ｃｄ２７４）の異常を指標としたｐｄ−１／ｐｄ−ｌ１阻害剤の治療効果予測方法 | |
| NZ597363A (en) | Prognosis prediction for colorectal cancer | |
| IN2012DN00707A (fr) | ||
| NZ586737A (en) | Compositions and methods of detecting tiabs | |
| Chen et al. | Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo | |
| NZ610482A (en) | Predictors of patient response to treatment with egf receptor inhibitors | |
| WO2021162981A3 (fr) | Méthodes et compositions pour l'identification du cancer de la prostate neuroendocrinien résistant à la castration | |
| WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
| MY145455A (en) | Diagnostic biomolecule(s) | |
| EP2304051B1 (fr) | Isoformes du mena humain servant de marqueurs de la sensibilité à l'inhibition de l'egfr dans des cellules humaines cancéreuses | |
| Wu et al. | LATS2 as a poor prognostic marker regulates non-small cell lung cancer invasion by modulating MMPs expression | |
| Chen et al. | Clinical and prognostic significance of Arl4c expression in colorectal cancer | |
| Volm et al. | Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases | |
| MA41742B1 (fr) | Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers. | |
| Li et al. | High expression of GPNMB predicts poor prognosis in head and neck squamous cell carcinoma | |
| WO2010149810A3 (fr) | Méthode in vitro pour le pronostic ou la prédiction de la réponse de patients souffrant de polyarthrite rhumatoïde au traitement avec des agents reconnaissant le récepteur membranaire cd 20 des lymphocytes b | |
| MA37437B1 (fr) | Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement |